The PTTG1/AURKA Axis Drives Acquired Anlotinib Resistance in Non-Small Cell Lung Cancer by Remodeling the Tumor Immune Microenvironment.
PTTG1 has been implicated in tumor progression and drug resistance, but its role in acquired anlotinib resistance in non-small cell lung cancer (NSCLC) remains unclear. This study investigated whether PTTG1 contributes to resistance and immune remodeling in NSCLC. We analyzed peripheral blood from NSCLC patients collec...